New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2020 May 12

PMID 32391381

Citations 42

Authors

Sugandha Bhatia

Peiyu Wang

Alan Toh

Erik W Thompson

Affiliations

Soon will be listed here.

Abstract

Tumor cells demonstrate substantial plasticity in their genotypic and phenotypic characteristics. Epithelial-mesenchymal plasticity (EMP) can be characterized into dynamic intermediate states and can be orchestrated by many factors, either intercellularly via epigenetic reprograming, or extracellularly via growth factors, inflammation and/or hypoxia generated by the tumor stromal microenvironment. EMP has the capability to alter phenotype and produce heterogeneity, and thus by changing the whole cancer landscape can attenuate oncogenic signaling networks, invoke anti-apoptotic features, defend against chemotherapeutics and reprogram angiogenic and immune recognition functions. We discuss here the role of phenotypic plasticity in tumor initiation, progression and metastasis and provide an update of the modalities utilized for the molecular characterization of the EMT states and attributes of cellular behavior, including cellular metabolism, in the context of EMP. We also summarize recent findings in dynamic EMP studies that provide new insights into the phenotypic plasticity of EMP flux in cancer and propose therapeutic strategies to impede the metastatic outgrowth of phenotypically heterogeneous tumors.

Citing Articles

Development and Characterization of Three Novel FGFR Inhibitor Resistant Cervical Cancer Cell Lines to Help Drive Cervical Cancer Research.

Bou Antoun N, Afshan Mahmood H, Walker A, Modjtahedi H, Grose R, Chioni A Int J Mol Sci. 2025; 26(5).

PMID: 40076427 PMC: 11898767. DOI: 10.3390/ijms26051799.

Liquid Biopsy in the Clinical Management of Cancers.

Ho H, Chung K, Kan C, Wong S Int J Mol Sci. 2024; 25(16).

PMID: 39201281 PMC: 11354853. DOI: 10.3390/ijms25168594.

Targeting the key players of phenotypic plasticity in cancer cells by phytochemicals.

Fakhri S, Moradi S, Abbaszadeh F, Faraji F, Amirian R, Sinha D Cancer Metastasis Rev. 2024; 43(1):261-292.

PMID: 38169011 DOI: 10.1007/s10555-023-10161-8.

Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC.

Gohlke L, Alahdab A, Oberhofer A, Worf K, Holdenrieder S, Michaelis M Int J Mol Sci. 2023; 24(19).

PMID: 37834189 PMC: 10573279. DOI: 10.3390/ijms241914742.

Feasibility of mass cytometry proteomic characterisation of circulating tumour cells in head and neck squamous cell carcinoma for deep phenotyping.

Payne K, Brooks J, Batis N, Khan N, El-Asrag M, Nankivell P Br J Cancer. 2023; 129(10):1590-1598.

PMID: 37735243 PMC: 10645808. DOI: 10.1038/s41416-023-02428-2.

References

Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

Grosselin K, Durand A, Marsolier J, Poitou A, Marangoni E, Nemati F . High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer. Nat Genet. 2019; 51(6):1060-1066. DOI: 10.1038/s41588-019-0424-9. View

Tachtsidis A, McInnes L, Jacobsen N, Thompson E, Saunders C . Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells. Clin Exp Metastasis. 2016; 33(6):521-50. PMC: 4947105. DOI: 10.1007/s10585-016-9796-8. View

Alonso-Alconada L, Muinelo-Romay L, Madissoo K, Diaz-Lopez A, Krakstad C, Trovik J . Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Mol Cancer. 2014; 13:223. PMC: 4190574. DOI: 10.1186/1476-4598-13-223. View

Sarioglu A, Aceto N, Kojic N, Donaldson M, Zeinali M, Hamza B . A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods. 2015; 12(7):685-91. PMC: 4490017. DOI: 10.1038/nmeth.3404. View

Debaugnies M, Sanchez-Danes A, Rorive S, Raphael M, Liagre M, Parent M . YAP and TAZ are essential for basal and squamous cell carcinoma initiation. EMBO Rep. 2018; 19(7). PMC: 6030692. DOI: 10.15252/embr.201845809. View

Ocana O, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S . Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell. 2012; 22(6):709-24. DOI: 10.1016/j.ccr.2012.10.012. View

Redfern A, Spalding L, Thompson E . The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome. Clin Exp Metastasis. 2018; 35(4):285-308. DOI: 10.1007/s10585-018-9906-x. View

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

10.

Lou Y, Diao L, Parra Cuentas E, Denning W, Chen L, Fan Y . Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res. 2016; 22(14):3630-42. PMC: 4947453. DOI: 10.1158/1078-0432.CCR-15-1434. View

11.

Chung V, Tan T, Ye J, Huang R, Lai H, Kappei D . The role of GRHL2 and epigenetic remodeling in epithelial-mesenchymal plasticity in ovarian cancer cells. Commun Biol. 2019; 2:272. PMC: 6656769. DOI: 10.1038/s42003-019-0506-3. View

12.

Kramer N, Walzl A, Unger C, Rosner M, Krupitza G, Hengstschlager M . In vitro cell migration and invasion assays. Mutat Res. 2012; 752(1):10-24. DOI: 10.1016/j.mrrev.2012.08.001. View

13.

McGranahan N, Swanton C . Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015; 27(1):15-26. DOI: 10.1016/j.ccell.2014.12.001. View

14.

Brabletz T . To differentiate or not--routes towards metastasis. Nat Rev Cancer. 2012; 12(6):425-36. DOI: 10.1038/nrc3265. View

15.

Klevebring D, Rosin G, Ma R, Lindberg J, Czene K, Kere J . Sequencing of breast cancer stem cell populations indicates a dynamic conversion between differentiation states in vivo. Breast Cancer Res. 2014; 16(4):R72. PMC: 4227057. DOI: 10.1186/bcr3687. View

16.

Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007; 7(6):415-28. DOI: 10.1038/nrc2131. View

17.

Witta S, Gemmill R, Hirsch F, Coldren C, Hedman K, Ravdel L . Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006; 66(2):944-50. DOI: 10.1158/0008-5472.CAN-05-1988. View

18.

Wang W, Peng J, Li X, Wang A, Bie Y, Shi L . Survival Mechanisms and Influence Factors of Circulating Tumor Cells. Biomed Res Int. 2018; 2018:6304701. PMC: 6236925. DOI: 10.1155/2018/6304701. View

19.

Lambert A, Pattabiraman D, Weinberg R . Emerging Biological Principles of Metastasis. Cell. 2017; 168(4):670-691. PMC: 5308465. DOI: 10.1016/j.cell.2016.11.037. View

20.

Milano A, Mazzetta F, Valente S, Ranieri D, Leone L, Botticelli A . Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice. Anal Cell Pathol (Amst). 2018; 2018:3506874. PMC: 5848062. DOI: 10.1155/2018/3506874. View